Adverse health consequences in COPD patients with rapid decline in FEV1 - evidence from the UPLIFT trial
Open Access
- 1 December 2011
- journal article
- research article
- Published by Springer Nature in Respiratory Research
- Vol. 12 (1) , 129
Abstract
The rate of decline in forced expiratory volume in 1 second (FEV1) is representative of the natural history of COPD. Sparse information exists regarding the associations between the magnitude of annualised loss of FEV1 with other endpoints.Keywords
This publication has 26 references indexed in Scilit:
- Tiotropium as a first maintenance drug in COPD: secondary analysis of the UPLIFT® trialEuropean Respiratory Journal, 2010
- Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trialEuropean Respiratory Journal, 2009
- COPD and Declining FEV1— Time to Divide and Conquer?New England Journal of Medicine, 2008
- A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2008
- Lung function decline in COPD trials: bias from regression to the meanEuropean Respiratory Journal, 2008
- Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease: Results from the TORCH StudyAmerican Journal of Respiratory and Critical Care Medicine, 2008
- Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax, 2002
- Effect of Inhaled Triamcinolone on the Decline in Pulmonary Function in Chronic Obstructive Pulmonary DiseaseNew England Journal of Medicine, 2000
- Long-Term Treatment with Inhaled Budesonide in Persons with Mild Chronic Obstructive Pulmonary Disease Who Continue SmokingNew England Journal of Medicine, 1999
- The natural history of chronic airflow obstruction.BMJ, 1977